Yarrow Bioscience (YARW) Cash from Operations (2017 - 2026)
Yarrow Bioscience's (YARW) quarterly Cash from Operations came in at 4081000.0 in Q1 2026, up 64.39% YoY from 2482476.57 in Q1 2025, and up 62.35% on a QoQ basis from 10839000.0 in Q2 2025.
Yarrow Bioscience (YARW) Cash from Operations (2017 - 2026) Analysis & Trends
Yarrow Bioscience (YARW) has 10 years of Cash from Operations data on file, last reported at 4081000.0 in Q1 2026.
- Quarterly Cash from Operations rose 64.39% year-over-year to 4081000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 35380000.0 (up 5.53% YoY) and the FY2025 annual result came in at 33124000.0, up 2.5% from the prior year.
- Cash from Operations improved to 4081000.0 in Q1 2026, from 10839000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 4081000.0 in Q1 2026 to a low of 11461000.0 in Q1 2025.
- A 5-year average of 7659600.0 and a median of 8225000.0 in 2022 frame the typical range for Cash from Operations.
- Annual changes were most pronounced in 2024 — Cash from Operations tumbled 75.18% — and 2026, when it soared 64.39%.
- Tracing YARW's Cash from Operations over 5 years: stood at 4811000.0 in 2022, then fell by 6.78% to 5137000.0 in 2023, then tumbled by 75.18% to 8999000.0 in 2024, then declined by 20.45% to 10839000.0 in 2025, then surged by 62.35% to 4081000.0 in 2026.
- The last three Cash from Operations figures came in at 4081000.0 (Q1 2026), 10839000.0 (Q2 2025), and 11461000.0 (Q1 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 728.46 Mn |
| 10 | Yarrow Bioscience | 31.25 Mn | 8.33 Mn | - | -2.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.00 Mn |
| Jun 30, 2026 | -2.00 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Mar 31, 2026 | -4.08 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Jun 30, 2025 | -10.84 Mn |
| Mar 31, 2025 | -11.46 Mn |
| Mar 31, 2025 | -11.46 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Dec 31, 2024 | -9.00 Mn |
| Sep 30, 2024 | -8.51 Mn |
| Sep 30, 2024 | -8.51 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Jun 30, 2024 | -8.48 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Mar 31, 2024 | -7.98 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Dec 31, 2023 | -5.14 Mn |
| Sep 30, 2023 | -5.15 Mn |
| Sep 30, 2023 | -5.15 Mn |